Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002391 · ClinicalTrials.gov registry record · Phase 3
The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs
A Phase 3 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002391: Completed Phase 3 study, sponsored by Glaxo Wellcome.
NCT00002391 is a Phase 3 study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002391, a Phase 3 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To compare the safety, tolerance, durability of the viral load response and the antiviral activity of the 1592U89/zidovudine(ZDV)/lamivudine (3TC) regimen vs. ZDV/3TC regimen. To determine the clinical efficacy of the two regimens as measured survival, disease progression, weight growth velocity, and neuropsychological or neurological changes. To assess the development of viral resistance and relative pharmacokinetics associated with each regimen.
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Abacavir sulfate
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
What the finished NCT00002391 record still lists
NCT00002391 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002391 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002391 about?
NCT00002391 is a clinical study titled "The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs". To compare the safety, tolerance, durability of the viral load response and the antiviral activity of the 1592U89/zidovudine(ZDV)/lamivudine (3TC) regimen vs. ZDV/3TC regimen. To determine the clinical efficacy of the two regimens as measured survival, disease progression, weight growth velocity, an...
What is the current status of trial NCT00002391?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002391?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Abacavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00002391?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.